

## Xbrane Biopharma to participate at Redeye Biosimilar/Drug Delivery 16 April

**Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") represented by Martin Åmark, CEO, will tomorrow participate at Redeye's capital markets day about Biosimilar/Drug Delivery.**

On April 16, at 09:55 AM, Martin Åmark, CEO, Xbrane Biopharma, will present the latest events and development in the Company at Redeye. The presentation will be live and can be followed at <https://www.redeye.se/events#/event/585887> where the presentation afterwards will be available on Xbrane's company page at Redeye Universe <https://www.redeye.se/company/xbrane-biopharma>.

### Contacts

---

Martin Åmark, CEO/ IR  
M: +46 (0) 763-093 777  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Susanna Helgesen, CFO  
M: +46 (0) 708-278 636  
E: [susanna.helgesen@xbrane.com](mailto:susanna.helgesen@xbrane.com)

### About Us

---

*Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit [www.xbrane.com](http://www.xbrane.com).*

### Attachments

---

[Xbrane Biopharma to participate at Redeye Biosimilar/Drug Delivery 16 April](#)